Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Altimmune, Inc.NASDAQ: ALT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $3.38M fell 15.9% year over year, behind the +4.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 31.6% from the prior quarter. Over 3 fiscal years it compounded at +25.7% a year.

Context

  • Stock-based compensation amounted to 39209.8% of revenue in FY2025, down 32755.2 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.9% toward the trailing-twelve-month pace of +4.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.38M-31.6% QoQ
Last fiscal yearDec 2025
$16.08M+11.7% YoY
LTMMar 2026
$15.44M+4.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.9%——
1 year+11.7%——
3-year CAGR+25.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
16.08M USD
Year-over-year change
+11.7%
4-year CAGR
+30.6%

Stock-Based Compensation vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.6% is the 6th highest of 9, against a peer median of +40.7%.
  • Stock-based compensation amounts to 42886.1% of revenue for ALT, versus a peer median of 22.8%.
ALT Competitors
Stock-Based Compensation for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$51.48M USD+103.6%+125.9%—
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M USD+17.1%-21.7%53.5%
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ABUSArbutus Biopharma CorporationLTM Mar 2026$18.43M USD+74.9%-1.1%9.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
ALTAltimmune, Inc.LTM Mar 2026$15.44M USD+4.6%+25.7%42886.1%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$5.08M USD+64.3%-10.8%7.1%
BMEABiomea Fusion, Inc.LTM Mar 2026$4.16M USD-75.9%-2.7%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$1.19M USD-32.6%-22.8%—
Peer median (excluding ALT) —+40.7%-6.8%22.8%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.